Activity Overview

This online, on-demand virtual symposium brings together renowned experts in advanced pancreatic ductal adenocarcinoma (PDAC). In this educational program, these experts discuss emerging approaches to target KRAS in advanced PDAC, framed in the discussion of challenging case scenarios where novel treatments could fit.

This educational activity is an archive of the live symposium held on April 11, 2026.

Target Audience

This educational activity is directed toward oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers involved in the diagnosis and treatment of pancreatic cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Interpret efficacy and safety data from recent and ongoing clinical trials of KRAS-targeted therapies for advanced PDAC
Apply emerging clinical evidence, molecular profiling results, and patient-specific factors to guide the selection and sequencing of targeted therapies in advanced PDAC

Show Me the Data®: From Mutation to Action — KRAS as a Therapeutic Target in PDAC

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Revolution Medicines.

Show Me the Data®: From Mutation to Action — KRAS as a Therapeutic Target in PDAC

GET STARTED WITH THIS PROGRAM:

Related Content